Virginia Cancer Specialists - Fairfax

Clinical research site in Fairfax, Virginia · 8613 LEE HWY # 200N, FAIRFAX, VA 22031-2171 · (703) 280-5390

Part of US Oncology

As of July 2026, 118 paid clinical trials are recruiting at Virginia Cancer Specialists - Fairfax in Fairfax, Virginia. Active studies at this site cover conditions such as Breast Cancer, Endometrial Cancer and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Virginia Cancer Specialists - Fairfax (118)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for Urothelial Cancer

74 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

61 locations incl. Los Angeles

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07392892·Phase 2, Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

for Pancreatic Cancer

28 locations incl. Fort Smith

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07409272·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for Carcinoma, Renal Cell

109 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

for Squamous Cell Carcinoma of Head and Neck

45 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07276399·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

for Pancreatic Cancer

29 locations incl. Los Angeles

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07252232·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostatic Neoplasms, Castration-Resistant

49 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07225946·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

for Non-small Cell Lung Cancer

28 locations incl. Fresno

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07195695·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for HER2-positive Breast Cancer

22 locations incl. Long Beach

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07102381·Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

104 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

for Follicular Lymphoma (FL)

32 locations incl. Fresno

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT06191744·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for Colon Adenocarcinoma

31 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06997497·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

54 locations incl. Daphne

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

43 locations incl. Birmingham

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

38 locations incl. Mobile

Sponsor: Incyte Corporation

Sex: Female·Age: 18 - 99

Code: NCT07023627·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

38 locations incl. Chandler

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06568939·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

36 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06158841·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 locations incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

for Metastatic Castration-resistant Prostate Cancer (mCRPC)

57 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136650·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

58 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

27 locations incl. Phoenix

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05650632·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

48 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

for Ovarian Cancer

32 locations incl. Birmingham

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

14 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05498428·Phase 2·Recruiting·Listed Aug 2022

Apply to this trial

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

for Extensive-stage Small-cell Lung Cancer

32 locations incl. Tucson

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT06712355·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

for Non-small Cell Lung Cancer

39 locations incl. Birmingham

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT06712316·Phase 2, Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Showing the 40 most relevant of 118 recruiting trials at this site. Browse all with filters →

More research sites in Fairfax

NEXT Virginia (72 trials)
Virginia Cancer Specialists (65 trials)
Inova Schar Cancer Institute (57 trials)
NEXT Oncology Virginia (29 trials)
NEXT Oncology (25 trials)
Virginia Cancer Specialists, PC (17 trials)
Inova Fair Oaks Hospital (14 trials)
Re:Cognition Health (7 trials)
Inova Schar Cancer (6 trials)
Inova Fairfax Hospital (5 trials)

Explore more

Paid clinical trials in Fairfax, VA · Virginia clinical trials